0.9796

3.96% -0.0404

Tevogen Bio Holdings Inc (TVGN)

Overview News Price History Discussions Forecast

Tevogen Bio Holdings Inc stock is traded at $0.9796, with a volume of 528.81K. It is down -3.96% in the last 24 hours and down -15.55% over the past month. Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Previous Close:

$1.02

Open:

$1.01

24h Volume:

528.81K

Relative Volume:

0.31

Market Cap:

$193.09M

Revenue:

Net Income/Loss:

$52.50M

P/E Ratio:

33.66

EPS:

0.0291

Net Cash Flow:

$-4.13M

1W Performance:

-2.04%

1M Performance:

-15.55%

6M Performance:

-29.01%

1Y Performance:

-57.13%

1-Day Range:

$0.92

$1.03

1-Week Range:

$0.92

$1.13

52-Week Range:

$0.2556

$3.09

Tevogen Bio Holdings Inc Stock (TVGN) Company Profile

Name

Tevogen Bio Holdings Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

646-807-8832

Address

15 INDEPENDENCE BOULEVARD, SUITE 410, WARREN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

TVGN's Discussions on Twitter

Compare TVGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TVGN Tevogen Bio Holdings Inc	0.9796	193.09M	0	52.50M	-4.13M	0.0291
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-04-25	Initiated	D. Boral Capital	Buy

Tevogen Bio Holdings Inc Stock (TVGN) Latest News

Apr 17, 2025

Tevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility - marketscreener.com

Apr 17, 2025

Tevogen Bio Signs Agreement with CD 8 Technology - TipRanks

Apr 17, 2025

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility - The Manila Times

Apr 17, 2025

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility - Bluefield Daily Telegraph

Apr 17, 2025

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility - Benzinga

Apr 17, 2025

Tevogen Bio Takes Control of Cell Therapy Production: Major Step Toward Manufacturing Independence - Stock Titan

Apr 17, 2025

Apr 16, 2025

WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market - The Manila Times

Apr 16, 2025

Apr 15, 2025

AI Breakthrough: Tevogen Bio Teams Up with Databricks for Revolutionary Immunotherapy Prediction Platform - Stock Titan

Apr 15, 2025

Apr 14, 2025

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald - The Manila Times

Apr 14, 2025

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald - The Globe and Mail

Apr 14, 2025

Apr 11, 2025

Tevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash Constraints - Seeking Alpha

Apr 11, 2025

Apr 10, 2025

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States - The Manila Times

Apr 10, 2025

Apr 09, 2025

Tevogen Takes on Drug Affordability Crisis with New US Manufacturing Division - Stock Titan

Apr 09, 2025

Apr 08, 2025

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs - The Manila Times

Apr 08, 2025

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s - Bluefield Daily Telegraph

Apr 08, 2025

Tevogen's Game-Changing AI Platform Accelerates T Cell Therapy Breakthroughs - Stock Titan

Apr 08, 2025

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission - The Manila Times

Apr 08, 2025

Apr 07, 2025

Tevogen reports high insider ownership amid market volatility By Investing.com - Investing.com South Africa

Apr 07, 2025

Tevogen reports high insider ownership amid market volatility - Investing.com Australia

Apr 07, 2025

Massive 74% Insider Stake Reveals Tevogen Bio Leadership's Unwavering Commitment - Stock Titan

Apr 07, 2025

Apr 02, 2025

Tevogen Bio Holdings Inc. SEC 10-K Report - TradingView

Apr 02, 2025

Apr 01, 2025

Tevogen Bio Holdings Delays Annual Report Filing - TipRanks

Apr 01, 2025

Mar 27, 2025

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast - The Manila Times

Mar 27, 2025

Mar 26, 2025

Thomas Butler steps down as Biomea CEO - BioCentury

Mar 26, 2025

Tevogen Bio's Ambitious $2B Revenue Target Backed by Leadership Excellence and Key Hire - Stock Titan

Mar 26, 2025

Mar 25, 2025

Tevogen Bio appoints new head of government affairs By Investing.com - Investing.com South Africa

Mar 25, 2025

Tevogen Bio appoints new head of government affairs - Investing.com

Mar 25, 2025

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Quantisnow

Mar 25, 2025

Tevogen Bio Appoints David E. Banko as Global Head of - GlobeNewswire

Mar 25, 2025

TSX Continues Higher as U.S. Trade Policy Appears to Soften - The Globe and Mail

Mar 25, 2025

Mar 21, 2025

SPY ETF News, 3/21/2025 - The Globe and Mail

Mar 21, 2025

Mar 19, 2025

Meta Stock Dips Below $600: A Buying Opportunity or a Red Flag? - The Globe and Mail

Mar 19, 2025

Mar 15, 2025

Tevogen Bio CEO reinforces commitment to retention of equity capital - MSN

Mar 15, 2025

Tevogen Bio’s chief scientific officer sells $253,935 in stock By Investing.com - Investing.com Australia

Mar 15, 2025

Tevogen bio’s chief scientific officer sells $253,935 in stock By Investing.com - Investing.com Australia

Mar 15, 2025

Mar 14, 2025

Tevogen Bio’s chief scientific officer sells $253,935 in stock - Investing.com India

Mar 14, 2025

Tevogen bio’s chief scientific officer sells $253,935 in stock - Investing.com

Mar 14, 2025

Tevogen Bio Holdings Officer Sells Shares to Cover Tax Obligations - TradingView

Mar 14, 2025

Mar 13, 2025

Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Short Interest Down 86.7% in February - Defense World

Mar 13, 2025

Mar 12, 2025

Tevogen Bio (NASDAQ:TVGN) Receives “Buy” Rating from D. Boral Capital - Defense World

Mar 12, 2025

Public market insider selling at Aura Minerals (ORA) - The Globe and Mail

Mar 12, 2025

Mar 11, 2025

Tevogen bio’s chief scientific officer sells shares worth $231,734 By Investing.com - Investing.com South Africa

Mar 11, 2025

Tevogen bio’s chief scientific officer sells shares worth $231,734 - Investing.com India

Mar 11, 2025

Mar 10, 2025

Tevogen Bio Files New US Patent for T Cell Vaccine Under Development -March 10, 2025 at 01:19 pm EDT - Marketscreener.com

Mar 10, 2025

Tevogen announces new patent filed for T cell vaccine - TipRanks

Mar 10, 2025

Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO - Marketscreener.com

Mar 10, 2025

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO - The Manila Times

Mar 10, 2025

Tevogen Bio Files Patent for Innovative T Cell Vaccine Targeting Entire Viral Genome to Combat Mutations - Nasdaq

Mar 10, 2025

Tevogen Bio Files Patent for AI-Powered T Cell Vaccine with Military Applications - StockTitan

Mar 10, 2025

Mar 09, 2025

Have Tevogen Bio Holdings Insiders Been Selling Stock? - simplywall.st

Mar 09, 2025

Mar 08, 2025